» Authors » Alex Castellarnau

Alex Castellarnau

Explore the profile of Alex Castellarnau including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 86
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Winchester S, Castellarnau A, Jabbar K, Nadir M, Ranasinghe K, Masramon X, et al.
Pharmaceutics . 2024 Sep; 16(9). PMID: 39339209
Background/objectives: Dendrimer-based astodrimer sodium nasal spray was assessed for its ability to reduce SARS-CoV-2 load in outpatients with COVID-19, which remains a severe illness for vulnerable groups. Methods: This was...
2.
Paull J, Luscombe C, Seta A, Heery G, Bobardt M, Gallay P, et al.
Sci Rep . 2024 Sep; 14(1):21259. PMID: 39261670
COVID-19 remains a severe condition for many including immunocompromised individuals. There remains a need for effective measures against this and other respiratory infections, which transmit via virus-laden droplets that reach...
3.
Castellarnau A, Heery G, Seta A, Luscombe C, Kinghorn G, Button P, et al.
Sci Rep . 2022 Jun; 12(1):10210. PMID: 35715644
Astodrimer sodium is a dendrimer molecule with antiviral and virucidal activity against SARS-CoV-2 and other respiratory viruses in vitro, and has previously been shown to be safe and well tolerated,...
4.
Paull J, Luscombe C, Castellarnau A, Heery G, Bobardt M, Gallay P
Viruses . 2021 Aug; 13(8). PMID: 34452519
Strategies to combat COVID-19 require multiple ways to protect vulnerable people from infection. SARS-CoV-2 is an airborne pathogen and the nasal cavity is a primary target of infection. The K18-hACE2...
5.
Paull J, Heery G, Bobardt M, Castellarnau A, Luscombe C, Fairley J, et al.
Antiviral Res . 2021 May; 191:105089. PMID: 34010661
An effective response to the ongoing coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will involve a range of complementary preventive modalities. The current studies...
6.
Schwebke J, Carter B, Waldbaum A, Agnew K, Paull J, Price C, et al.
Eur J Obstet Gynecol Reprod Biol X . 2021 Feb; 10:100121. PMID: 33537666
Objective: The objective of the study was to confirm the efficacy and safety of Astodrimer 1% Gel to prevent recurrence of bacterial vaginosis. Study Design: 864 women with a diagnosis...
7.
Waldbaum A, Schwebke J, Paull J, Price C, Edmondson S, Castellarnau A, et al.
PLoS One . 2020 May; 15(5):e0232394. PMID: 32365097
Background: Astodrimer Gel contains a novel dendrimer intended to treat and prevent bacterial vaginosis. We assessed the efficacy and safety of Astodrimer Gel for treatment of bacterial vaginosis. Methods: 132...
8.
Chavoustie S, Carter B, Waldbaum A, Donders G, Peters K, Schwebke J, et al.
Eur J Obstet Gynecol Reprod Biol . 2019 Dec; 245:13-18. PMID: 31812702
Objective: Astodrimer is a dendrimer formulated in a vaginal gel to treat bacterial vaginosis (BV) and prevent recurrence. The objective of these studies was to confirm the efficacy and safety...
9.
Castellarnau A, Werner M, Gunthner R, Jakob M
Kidney Int . 2010 Jul; 78(9):920-5. PMID: 20631678
Real-time determination of Kt/V can be provided by monitoring ultraviolet absorbance of solutes in spent dialysate. This not only overcomes dependency on error-prone pre- and post-dialysis blood sampling; it circumvents...